Children's Medical Research Institute

DiNAQOR Announces Research Collaboration with Children's Medical Research Institute to Develop Novel, Cardiac Specific Capsids

Retrieved on: 
Monday, January 10, 2022
Cardiac muscle, Research, Technology, Patient, LRP, Virus, EHT, CMRI, Degenerative disease, MBA, Protein, Gene, CEO, Kidney, Children's Medical Research Institute, Solution, Health, University, Heart, Associate, AAV, Vaccine, Pharmaceutical industry, NSW, Westmead

"Our aim is to develop new capsids that can target the heart more efficiently at lower doses."

Key Points: 
  • "Our aim is to develop new capsids that can target the heart more efficiently at lower doses."
  • DiNAQOR will screen capsids for transduction systemically and tailor AAV capsids for loco-regional perfusion (LRP) administration.
  • DiNAQOR's LRP system enables gene therapies to be routed directly to the cardiac muscle, maximizing biodistribution and transduction of the cardiac cells.
  • Children's Medical Research Institute (CMRI) is an award-winning state-of-the-art medical research facility, dedicated to researching the genes and proteins important for health and human development.

Oracle Announces New AI Services for Oracle Cloud Infrastructure

Retrieved on: 
Wednesday, November 3, 2021
Cloud, Central processing unit, Solution, Visage SDK, Oracle Cloud, Hauptman-Woodward Medical Research Institute, Research, NVIDIA, Interval (mathematics), Industry, Goal, Neoplasm, Children's Medical Research Institute, CMRI, Organization, Human, Child, Transport, Explainable artificial intelligence, Machine learning, NYSE, Language, Index, Graphics processing unit, Data science, Business process, Digital assistant, Social media, Collection, Anomaly, Forecasting, CEO, Oracle Cloud Platform, REST, Outsourcing, Cell, Artificial intelligence, API, Classification, AI control problem, OCI, AI, Information technology, Medical device, Software

AUSTIN, Texas, Nov. 3, 2021 /PRNewswire/ --Oracle today announced availability of Oracle Cloud Infrastructure (OCI) AI services , a collection of services that make it easier for developers to apply AI services to their applications without requiring data science expertise.

Key Points: 
  • AUSTIN, Texas, Nov. 3, 2021 /PRNewswire/ --Oracle today announced availability of Oracle Cloud Infrastructure (OCI) AI services , a collection of services that make it easier for developers to apply AI services to their applications without requiring data science expertise.
  • "It's essential for organizations to bridge the gap between the promise of AI and implementing AI that helps them achieve real results," said Greg Pavlik, chief technology officer, Oracle Cloud Platform.
  • "Oracle is best positioned to realize the value of AI through our industry-leading expertise in enterprise applications and enterprise data, our next-generation cloud infrastructure, and our deep commitment to building AI services and solutions."
  • Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud.

Zogenix to Host Key Opinion Leader Webinar on Thymidine Kinase 2 Deficiency and MT-1621

Retrieved on: 
Monday, November 1, 2021
Myopathy, CDD, European Medicines Agency, Complutense University of Madrid, Natural history, Peaceful transition of power, Clinical trial, Columbia University, Albert Einstein College of Medicine, Publication, Research institute, Division, GLOBE, Degenerative disease, Research, Molecular biology, Children's Medical Research Institute, TK2, Epilepsy, KOL, Montreal Neurological Institute and Hospital, Columbia University Irving Medical Center, Pyrimidine, Lennox–Gastaut syndrome, Lucy, Continuation, Q&A, ALS, Seizure, DNA, Fenfluramine, Dravet syndrome, Neurological Institute of New York, NASDAQ, FDA, Neuromuscular medicine, Mitochondrial disease, Muscle, Pharmaceutical industry

EMERYVILLE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will host a key opinion leader (KOL) webinar on thymidine kinase 2 deficiency (TK2d) and MT-1621 on Monday, November 8, 2021, at 12:00 PM Eastern Time.

Key Points: 
  • EMERYVILLE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will host a key opinion leader (KOL) webinar on thymidine kinase 2 deficiency (TK2d) and MT-1621 on Monday, November 8, 2021, at 12:00 PM Eastern Time.
  • Dr. Galer will discuss the ongoing late-stage MT-1621 clinical program and remaining pathway to regulatory submissions.
  • She holds a doctorate from the Complutense University of Madrid with the thesis entitled: "Application of Personalized Medicine in Mitochondrial Pathology: treatment with pyrimidine nucleosides in thymidine kinase 2 deficiency (TK2d)".
  • The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency.

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Retrieved on: 
Tuesday, October 19, 2021
Biotechnology, General Health, Health, Genetics, Pharmaceutical, University, Doctor of Philosophy, Cystic fibrosis, Cell, GTC, Discovery, News, Organization, CFTR, National Institute for Health Research, Achievement, Lung, OXB, Â, Oxford BioMedica, Trust, Department, Cystic Fibrosis Trust, Department of Health and Social Care, Exercise, Research, Social work, Intellectual property, Medical research, Degenerative disease, Leadership, National Institute, Knowledge, Children's Medical Research Institute, Patient, Wellcome, Imperial College London, CF, Dysfunction, Department of Zoology, University of Oxford, Partnership, Infection, Efficiency, IP Group, Boehringer Ingelheim, Global Health Innovative Technology Fund, Pharmaceutical industry

The GTC is additionally contributing its knowledge in pre-clinical research and clinical gene therapy development.

Key Points: 
  • The GTC is additionally contributing its knowledge in pre-clinical research and clinical gene therapy development.
  • OXB is adding its leading competence in manufacturing lentiviral vector-based therapies to Boehringer Ingelheims expertise in the development of novel breakthrough therapies for respiratory diseases.
  • This partnership is central to our companys mission of delivering life changing gene therapies to patients and has the potential to provide a new therapeutic option for many cystic fibrosis patients globally.
  • David Ramsden, Chief Executive of the Cystic Fibrosis Trust said: It is great news that Boehringer Ingelheim have committed to the next stage of the development of a gene therapy treatment for people with cystic fibrosis.